Advertisement

Systemische und rückenmarknahe Therapie mittels Schmerzpumpen und Ports

  • Hans Georg Kress
  • Birgit Kraft

Zusammenfassung

Bei schwer behandelbaren Krebsschmerzen, die auch unter Ausschöpfung aller enteralen und/oder transdermalen Optionen des WHO-Stufenschema nicht oder nur mit inakzeptablen Nebenwirkungen beherrschbar sind, stellen intravenöse, subkutane und vor allem rückenmarknahe Applikationswege guteunderfolgversprechende Alternativen dar [4, 6, 8, 12, 9, 20].Hierzu stehen neben externen, druckbetriebenen Einmalreservoirpumpen, vor allem externe, mikroprozessorgesteuerte, programmierbare Patienten-kontrollierte Pumpen (PCA-Pumpen), implantierbare Portsysteme für intravenösen, epiduralen oder intrathekalen Zugang sowie vollständig implantierbare gas- oder batteriebetriebene Pumpen (ausschließlich zur Intrathekalgabe) verschiedener Hersteller zurVerfügung. Insgesamt bleiben diese invasivenVerfahren wenigen Patienten vorbehalten und werden — abhängig von der Spezialisierung der jeweiligen Einrichtung — nur bei ca. 5%bis 10%der Tumorschmerzbehandlungen notwendig.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aldrete JA (1995) Epidural fibrosis after permanent catheter insertion and infusion. J Pain Symptom Manage 10: 624–631PubMedCrossRefGoogle Scholar
  2. 2.
    Bedder MD, Burchiel K, Larson A (1991) Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 6: 368–373PubMedCrossRefGoogle Scholar
  3. 3.
    Coffey RJ, Burchiel K (2002) Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 50: 78–86PubMedGoogle Scholar
  4. 4.
    Cools HJ, Berkhout AM, De Bock GH (1996) Subcutaneous morphine infusion by syringe driver for terminally ill patients. Age Ageing 25: 206–208PubMedCrossRefGoogle Scholar
  5. 5.
    Dahm P, Nitescu P, Appelgren L, Curelaru I (1998) Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and/or bupivacaine in refractory nonmalignant pain: a comparison between the epidural and the intrathecal approach with externalized or implanted catheters and infusion pumps. Clin J Pain 14: 4–16PubMedCrossRefGoogle Scholar
  6. 6.
    Deer T, Krames ES, Hassenbusch SJ, Burton A, Caraway D, Dupen S, Eisenach J, Erdek M, Grigsby E, Kim P, Levy R, Mc Dowell G, Mekhail N, Panchal S, Prager J, Rauck R, Saulino M, Sitzman T, Staats P, Stanton-Hicks M, Stearns L, Willis D, Witt W, Follet K, Huntoon M, Liem L, Rathmell J, Wallace M, Buchser E, Cousins M, Ver Donck A (2007) Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 10(4): 300–328PubMedCrossRefGoogle Scholar
  7. 7.
    Devulder J, Ghys L, Dhondt W, Rolly G (1994) Spinal analgesia in terminal care: risk versus benefit. J Pain Symptom Manage 9: 75–81PubMedCrossRefGoogle Scholar
  8. 8.
    Drexel H, Dzien A, Spiegel RW, Lang AH, Breier C, et al (1989) Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 36: 169–176PubMedCrossRefGoogle Scholar
  9. 9.
    Eisenach JC, Rauck RL, Buzzanell C, Lysak SZ (1989) Epidural clonidine analgesia for intractable cancer pain: Phase I. Anesthesiology 71: 647–652PubMedCrossRefGoogle Scholar
  10. 10.
    Eisenach JC, Du Pen S, Dubois M, Miguel R, Allin D (1995) Epidural clonidine analgesia for intractable cancer pain. Pain 61: 391–399PubMedCrossRefGoogle Scholar
  11. 11.
    Hassenbusch S, Burchiel K, Coffey RJ, Cousins MJ, Deer T, Hahn MB, Pen SD, Follett KA, Krames E, Rogers JN, Sagher O, Staats PS, Wallace M, Willis KD (2002) Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med 3: 313–323PubMedCrossRefGoogle Scholar
  12. 12.
    Hogan Q, Haddox JD, Abram S, Weissman D, Taylor ML, Janjan N (1991) Epidural opiates and local anesthetics for the management of cancer pain. Pain 46: 271–279PubMedCrossRefGoogle Scholar
  13. 13.
    Iida H, Ohata H, Iida M, Nagase K, Uchida M, Dohi S (2001) The differential effects of stereoisomers of ropivacaine and bupivacaine on cerebral pial arterioles in dogs. Anesth Analg 93(6): 1552–1556PubMedCrossRefGoogle Scholar
  14. 14.
    Krames ES (1993) Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage 8: 36–46PubMedCrossRefGoogle Scholar
  15. 15.
    Kress HG, Simpson KH, Marchettini P, Ver Donck A, Varrassi G (2009) Intrathecal therapy: what has changed with the introduction of ziconotide. Pain Pract 9: 338–47PubMedCrossRefGoogle Scholar
  16. 16.
    Lanning RM, Hrushesky WJM (1990) Cost comparison of wearable and implantable drug delivery systems. Proc ASCO 9: 322Google Scholar
  17. 17.
    McMillan MR, Doud T, Nugent W (2003) Catheter-associated masses in patients receiving intrathecal analgesic therapy. Anesth Analg 96: 186–190PubMedGoogle Scholar
  18. 18.
    Müller H (2001) Spinale Opioidanalgesie. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wissenschaftliche Verlagsges, Stuttgart, S 441–456Google Scholar
  19. 19.
    Nitescu P, Appelgren L, Hultman E, Lindner LE, Sjoberg M, Curelaru I (1991) Longterm, open catheterization of the spinal subarachnoid space for continuous infusion of narcotic and bupivacaine in patients with „refractory“ cancer pain. Clin J Pain 7: 143–161PubMedCrossRefGoogle Scholar
  20. 20.
    Patt RB (ed) (1993) Cancer pain. Lippincott, Philadelphia, pp 329–341Google Scholar
  21. 21.
    Samuelsson H, Malmberg F, Eriksson M, Hedner T (1995) Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 10: 105–112PubMedCrossRefGoogle Scholar
  22. 22.
    Sator-Katzenschlager S, Deusch E, Maier P, Spacek A, Kress HG (2001) The long-term antinociceptive effect of intrathecal S(+)-ketamine in a patient with established morphine tolerance. Anesth Analg 93: 1032–1034PubMedCrossRefGoogle Scholar
  23. 23.
    Sjoberg M, Nitescu P, Appelgren L, Curelaru I (1994) Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Anesthesiology 80: 284–297PubMedCrossRefGoogle Scholar
  24. 24.
    Smith DE (1990) Spinal opioids in the home and hospice setting. J Pain Symptom Manage 5: 175–182PubMedCrossRefGoogle Scholar
  25. 25.
    Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH (2005) Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. Pain 117(1–2): 813–818Google Scholar
  26. 26.
    Waldmann CS, Eason JR, Rambohul E, Hanson GC (1984) Serum morphine levels. A comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthesia 39: 768–771PubMedCrossRefGoogle Scholar
  27. 27.
    Yaksh TL (1996) Intrathecal and epidural opiates: a review. In: Campbell JN (ed) Pain 1996 — an updated review. IASP Press, Seattle, S 381–393Google Scholar
  28. 28.
    Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ (2002) Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 3: 300–312PubMedCrossRefGoogle Scholar
  29. 29.
    Yaksh TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, Sommer C, Meschter C, Richter PJ, Hildebrand KR (2003) Chronically infused intrathecal morphine in dogs. Anesthesiology 99: 174–187PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2012

Authors and Affiliations

  • Hans Georg Kress
  • Birgit Kraft

There are no affiliations available

Personalised recommendations